# A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

> **NCT01256411** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 341 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** LCZ696
- **DRUG:** Amlodipine
- **DRUG:** Hydrochlorothiazide (HCTZ)

## Key facts

- **NCT ID:** NCT01256411
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2015-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01256411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01256411, "A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01256411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*